GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
The biological activity of the enzyme glycogen synthase kinase-3 (GSK3) is fulfilled by two paralogs named GSK3α and GSK3β, which possess both redundancy and specific functions. The upregulated activity of these proteins is linked to the development of disorders such as neurodegenerative disorders (ND) and cancer. Although various chemical inhibitors of these enzymes restore the brain functions in models of ND such as Alzheimer’s disease (AD), and reduce the proliferation and survival of cancer cells, the particular contribution of each paralog to these effects remains unclear as these molecules downregulate the activity of both paralogs with a similar efficacy. Moreover, given that GSK3 paralogs phosphorylate more than 100 substrates, the simultaneous inhibition of both enzymes has detrimental effects during long-term inhibition. Although the GSK3β kinase function has usually been taken as the global GSK3 activity, in the last few years, a growing interest in the study of GSK3α has emerged because several studies have recognized it as the main GSK3 paralog involved in a variety of diseases. This review summarizes the current biological evidence on the role of GSK3α in AD and various types of cancer. We also provide a discussion on some strategies that may lead to the design of the paralog-specific inhibition of GSK3α.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Specific inhibition of GSK3 may be beneficial in acute myeloid leukemia. Left panel: The selective inhibitors BRD-0705, Tivantinib, and others reported by Neuman et al. [89] promote the differentiation of acute myeloid leukemia (AML) cells without the stabilization of β-catenin and without deleterious effects [29,43,90,91]. Right panel: The inhibition of both GSK3 paralogs leads to deleterious effects and promotes β-catenin stabilization and cell proliferation [29,85].](https://figures.cochat.ai/paper-figures/04c9984b78794fa2b8d8c42cf62634cf/gsk3-an-important-paralog-in-neurodegenerative-disorders-and-cancer-figure-2.jpg)
![Figure 3 Molecular docking of GSK3α/β inhibitors. The ligands coupled to the GSK3α simulated protein GSK3β–D133E (white-gray surface) by Autodock Vina are color-coded as follows: 15b [104], golden; EHT1610 [97], green; BRD0705 [29], gray; and Λ-OS1 [96], blue. The arrows point to the region where the ligands interact with the cavity proposed by Wagner et al. [29]. Image generated with Autodock tools 1.5.6.](https://figures.cochat.ai/paper-figures/879abf51ac384a63a59f0d10db4af4da/gsk3-an-important-paralog-in-neurodegenerative-disorders-and-cancer-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As the role of GSK-3α in promoting Aβ production and tau phosphorylation in AD models is recognized”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [496]
The cited source says what the claim attributes to it.
In the citing paper
“selective inhibition of GSK-3α has emerged as a promising therapeutic strategy.494,496,497”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [496]
The cited source says what the claim attributes to it.
In the citing paper
“It is noteworthy that simultaneous inhibition of both GSK-3α and GSK-3β could excessively activate the wnt/β-catenin pathway, leading to abnormal cell proliferation and other detrimental effects.496,498”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [496]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Martin, M., Rehani, K., Jope, R. S., & Michalek, S. M. (2005) · Nature Immunology · doi:10.1038/ni1221 · Cited by 1,080
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Interactomes of Glycogen Synthase Kinase-3 Isoforms
Cormier, K. W., Larsen, B. G., Gingras, A., & Woodgett, J. R. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00825 · Cited by 23
Wang, X., Shuai, W., Yang, P., Liu, Y., Zhang, Y., & Wang, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102584 · Cited by 20
Targets and mechanisms of Alpinia oxyphylla Miquel fruits in treating neurodegenerative dementia
Zeng, P. H., Liu, Y.-C., Wang, X., Ye, C., Sun, Y., Su, H.-F., Qiu, S.-W., Li, Y., Wang, Y., Wang, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1013891 · Cited by 18
Soltan, O. M., Abdelrahman, K. S., Bass, A. K. A., Takizawa, K., Narumi, A., & Konno, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107651 · Cited by 15
Metadata
- Authors
- Silva-García, O., Cortés-Vieyra, R., Mendoza-Ambrosio, F. N., Ramírez-Galicia, G., & Baizabal-Aguirre, V. M.
- Affiliations
- Universidad del Papaloapan (MX)
- Mexican Social Security Institute (MX)
- Departamento de Química Teórica, Universidad del Papaloapan, Oaxaca 68301, Mexico
- Centro Multidisciplinario de Estudios en Biotecnología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Michoacana de San Nicolás de Hidalgo, Michoacán 58893, Mexico
- Corresponding author
- Silva-García, Octavio
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2020-12-16
- Volume
- 10
- Issue
- 12
- Pages
- 1683
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC7765659
- OpenAlex
- W3112569863
- Cited by
- 17
- References
- 122
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 1
- FWCI
- 0.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Consejo Nacional de Ciencia y Tecnología
- Universidad Michoacana de San Nicolás de Hidalgo
- Instituto Mexicano del Seguro Social
- Coordinación de la Investigación Científica
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- GSK3α, glycogen synthase kinase-3, neurodegenerative diseases, Alzheimer's disease, cancer, kinase inhibitors, protein phosphorylation, enzyme redundancy
- MeSH terms
- Alzheimer Disease, Animals, Brain Neoplasms, Female, Humans, Lung Neoplasms, Male, Multiple Myeloma, Phosphorylation, Prostatic Neoplasms, Signal Transduction, Leukemia, Myeloid, Acute, Protein Serine-Threonine Kinases, HL-60 Cells, Neurodegenerative Diseases, Inhibitory Concentration 50, Carcinoma, Pancreatic Ductal, Glycogen Synthase Kinase 3, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer. https://app.cochat.ai/papers/10.3390/biom10121683
- The paper
- Silva-García, O., Cortés-Vieyra, R., Mendoza-Ambrosio, F. N., Ramírez-Galicia, G., & Baizabal-Aguirre, V. M. (2020). GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer. Biomolecules. https://doi.org/10.3390/biom10121683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.